Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Shares withheld for taxes Chief Financial Officer gave up 35,879 shares (to pay taxes)
  2. 4 Shares withheld for taxes Chief Technical Officer gave up 8,351 shares (to pay taxes)
  3. 4 Shares withheld for taxes General Counsel gave up 23,628 shares (to pay taxes)
  4. 8-K Event Regulation FD disclosure
  5. S-8 Other Securities Offered to Employees in Benefit Plans
  6. 10-K Report Annual Report
  7. 8-K Event Results of operations
  8. 4 Open-market sale General Counsel sold 3,000 shares at $6.85 ($20,550)
  9. SC 13G Stake Amended Statement of Ownership
  10. SC 13G/A Stake Amended Statement of Ownership
  11. SC 13G Stake Amended Statement of Ownership
  12. SC 13G Stake Amended Statement of Ownership
  13. SC 13G Stake Amended Statement of Ownership
  14. 4 Grant or award EVP of R&D acquired 251,908 shares (grant or award)
  15. 4 Open-market sale General Counsel sold 3,000 shares at $7.04 ($21,120)
  16. 3 Insider Initial Statement of Ownership
  17. 8-K Event Executive or director change
  18. 4 Open-market sale General Counsel sold 5,602 shares at $7.53 ($42,186)
  19. 8-K Event Other events
  20. S-3ASR Offering Registration Statement

Page 15 of 30 · 587 filings